Lion Point Capital, LP has disclosed 21 total holdings in their latest 13F filing with the SEC for the portfolio
date of 2025-03-31. The current portfolio value is calculated to be $16.00 Mil. The turnover rate is 7%.
In Lion Point Capital, LP's current portfolio as of 2025-03-31, the top 5 holdings are
Insmed Inc (INSM), Ardelyx Inc (ARDX), Mineralys Therapeutics Inc (MLYS), Fennec Pharmaceuticals Inc (FENC), Kiniksa Pharmaceuticals International PLC (KNSA), not including call and put options.
Lion Point Capital, LP did not buy any new stocks in the current portfolio.
Please visit the "Current Portfolio" tab to see the current and past 13F holdings for Lion Point Capital, LP, as well as holding map,
valuations for each stock, which positions are undervalued, have low PE Ratios, are considered high quality and recently traded at
52-week lows, etc.
Please visit the "Stock Picks" tab to see the latest guru trades and stock picks for Lion Point Capital, LP, which include data from
13F quarterly reports, 13D/G beneficial ownership reports and form 4 insider ownership change reports.
Please visit the "Summary" page to see the top 10 holdings, recent stock picks, performance, sector / industry breakdown details, as well as past holding history summary for Lion Point Capital, LP.